BMC ophthalmology · 2026
Evaluation of serum semaphorin-3A and interleukin 6 levels in patients with neovascular age-related macular degeneration.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okutucu Murat, Arpa Medeni
Аннотация
PURPOSE: To determine whether serum semaphorin 3 A (Sema3A) and interleukin 6 (IL-6) play a role in the common etiopathogenesis of nAMD and nAMD-associated systemic diseases by evaluating these mediators levels.
METHODS: This prospective case-control study included 74 patients divided into nAMD (n = 33) and a control group (n = 41). Serum Sema3A and IL-6 levels were analyzed using the enzyme-linked immunosorbent assay.
RESULTS: The nAMD group had a statistically higher IL-6 level [5,9 (1-16,9) pg/mL], compared to the control group [1,5 (0,38 - 2,96) pg/mL] (p < 0.001). On the other hand, the Sema3A level of the nAMD group was lower at [26,3 (11,5-100) ng/mL] compared to the control group at [44,7 (16,8-100) ng/mL] (p < 0.001). The IL-6 level in the hypertension (+) group [2,5 (0,5-16,9) pg/ml] was significantly higher than that in the hypertension (-) group [1,7 (0,4-15,3) pg/ml] (p < 0.001). No significant difference was found between the hypertension (+) and hypertension (-) groups in terms of SEMA3A level. There was a negative correlation between serum SEMA3A and serum IL-6 levels of the whole participants (p < 0.001, r=-0.471).
CONCLUSIONS: Decreased levels of the anti-inflammatory and anti-angiogenic mediator Sema3A and increased levels of inflammatory mediator IL-6 detected in nAMD suggest that these molecules may play a role in systemic manifestations of this syndrome, such as inflammation, cardiovascular diseases, atrial fibrillation, and Alzheimer's disease.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: This prospective case-control study included 74 patients divided into nAMD (n = 33) and a control group (n = 41). Serum Sema3A and IL-6 levels were analyzed using the enzyme-linked immunosorbent assay.
RESULTS: The nAMD group had a statistically higher IL-6 level [5,9 (1-16,9) pg/mL], compared to the control group [1,5 (0,38 - 2,96) pg/mL] (p < 0.001). On the other hand, the Sema3A level of the nAMD group was lower at [26,3 (11,5-100) ng/mL] compared to the control group at [44,7 (16,8-100) ng/mL] (p < 0.001). The IL-6 level in the hypertension (+) group [2,5 (0,5-16,9) pg/ml] was significantly higher than that in the hypertension (-) group [1,7 (0,4-15,3) pg/ml] (p < 0.001). No significant difference was found between the hypertension (+) and hypertension (-) groups in terms of SEMA3A level. There was a negative correlation between serum SEMA3A and serum IL-6 levels of the whole participants (p < 0.001, r=-0.471).
CONCLUSIONS: Decreased levels of the anti-inflammatory and anti-angiogenic mediator Sema3A and increased levels of inflammatory mediator IL-6 detected in nAMD suggest that these molecules may play a role in systemic manifestations of this syndrome, such as inflammation, cardiovascular diseases, atrial fibrillation, and Alzheimer's disease.
CLINICAL TRIAL NUMBER: Not applicable.